{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:11:01Z","timestamp":1777936261090,"version":"3.51.4"},"reference-count":33,"publisher":"Japan Atherosclerosis Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.5551\/jat.66076","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T22:08:28Z","timestamp":1769983708000},"page":"643-654","source":"Crossref","is-referenced-by-count":0,"title":["TLR4 Inhibition Attenuates Vascular Remodeling in A Mouse Model of Chronic Kidney Disease"],"prefix":"10.5551","volume":"33","author":[{"given":"Tomohiro","family":"Shirouzu","sequence":"first","affiliation":[{"name":"The Second Department of Internal Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichiro","family":"Koga","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasanbadrakh","family":"Orkhonselenge","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Nagata","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Kidney Center, Hospital of the University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Kataoka","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kovesdy CP: Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011), 2022; 12: 7-11","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) London GM: Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol, 2003; 14: S305-309","DOI":"10.1097\/01.ASN.0000081664.65772.EB"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Shanahan CM: Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol, 2013; 9: 661-670","DOI":"10.1038\/nrneph.2013.176"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Briet M, Collin C, Karras A, Laurent S, Bozec E, Jacquot C, Stengel B, Houillier P, Froissart M, Boutouyrie P and Nephrotest Study G: Arterial remodeling associates with CKD progression. J Am Soc Nephrol, 2011; 22: 967-974","DOI":"10.1681\/ASN.2010080863"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Bover J, Aguilar A, Arana C, Molina P, Lloret MJ, Ochoa J, Berna G, Gutierrez-Maza YG, Rodrigues N, D\u2019Marco L and Gorriz JL: Clinical Approach to Vascular Calcification in Patients With Non-dialysis Dependent Chronic Kidney Disease: Mineral-Bone Disorder-Related Aspects. Front Med (Lausanne), 2021; 8: 642718","DOI":"10.3389\/fmed.2021.642718"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Yamada S and Nakano T: Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD. J Atheroscler Thromb, 2023; 30: 835-850","DOI":"10.5551\/jat.RV22006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P and Tracey KJ: High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med, 2008; 14: 109-115","DOI":"10.2119\/2007-00107.Bruchfeld"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Grabulosa CC, Manfredi SR, Canziani ME, Quinto BMR, Barbosa RB, Rebello JF, Batista MC, Cendoroglo M and Dalboni MA: Chronic kidney disease induces inflammation by increasing Toll-like receptor-4, cytokine and cathelicidin expression in neutrophils and monocytes. Exp Cell Res, 2018; 365: 157-162","DOI":"10.1016\/j.yexcr.2018.02.022"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Faustino VD, Arias SCA, Ferreira Avila V, Foresto-Neto O, Zambom FFF, Machado FG, Machado Dos Reis L, Malheiros D, Volpini RA, Camara NOS, Zatz R and Fujihara CK: Simultaneous activation of innate and adaptive immunity participates in the development of renal injury in a model of heavy proteinuria. Biosci Rep, 2018; 38:","DOI":"10.1042\/BSR20180762"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Zhou Z, Ni J, Li J, Huo C, Miao N, Yin F, Cheng Q, Xu D, Xie H, Chen P, Zheng P, Zhang Y, Zhou L, Zhang W, Yu C, Liu J and Lu L: RIG-I aggravates interstitial fibrosis via c-Myc-mediated fibroblast activation in UUO mice. J Mol Med (Berl), 2020; 98: 527-540","DOI":"10.1007\/s00109-020-01879-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Zhang Y, Peng W, Ao X, Dai H, Yuan L, Huang X and Zhou Q: TAK-242, a Toll-Like Receptor 4 Antagonist, Protects against Aldosterone-Induced Cardiac and Renal Injury. PLoS One, 2015; 10: e0142456","DOI":"10.1371\/journal.pone.0142456"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Souza AC, Tsuji T, Baranova IN, Bocharov AV, Wilkins KJ, Street JM, Alvarez-Prats A, Hu X, Eggerman T, Yuen PS and Star RA: TLR4 mutant mice are protected from renal fibrosis and chronic kidney disease progression. Physiol Rep, 2015; 3:","DOI":"10.14814\/phy2.12558"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kawamoto T, Ii M, Kitazaki T, Iizawa Y and Kimura H: TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol, 2008; 584: 40-48","DOI":"10.1016\/j.ejphar.2008.01.026"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Matsunaga N, Tsuchimori N, Matsumoto T and Ii M: TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol, 2011; 79: 34-41","DOI":"10.1124\/mol.110.068064"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M, Hazeki O, Akira S, Iizawa Y and Ii M: Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol, 2009; 157: 1250-1262","DOI":"10.1111\/j.1476-5381.2009.00297.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Connolly MG, Potter OV, Sexton AR and Kohman RA: Effects of Toll-like receptor 4 inhibition on spatial memory and cell proliferation in male and female adult and aged mice. Brain Behav Immun, 2021; 97: 383-393","DOI":"10.1016\/j.bbi.2021.06.008"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gu HF, Li N, Xu ZQ, Hu L, Li H, Zhang RJ, Chen RM, Zheng XL, Tang YL and Liao DF: Chronic Unpredictable Mild Stress Promotes Atherosclerosis via HMGB1\/TLR4-Mediated Downregulation of PPARgamma\/LXRalpha\/ABCA1 in ApoE(-\/-) Mice. Front Physiol, 2019; 10: 165","DOI":"10.3389\/fphys.2019.00165"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Bhattacharyya S, Wang W, Tamaki Z, Shi B, Yeldandi A, Tsukimi Y, Yamasaki M and Varga J: Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis. Front Immunol, 2018; 9: 2434","DOI":"10.3389\/fimmu.2018.02434"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Zhang Z, Lin C, Peng L, Ouyang Y, Cao Y, Wang J, Friedman SL and Guo J: High mobility group box 1 activates Toll like receptor 4 signaling in hepatic stellate cells. Life Sci, 2012; 91: 207-212","DOI":"10.1016\/j.lfs.2012.07.009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kren S and Hostetter TH: The course of the remnant kidney model in mice. Kidney Int, 1999; 56: 333-337","DOI":"10.1046\/j.1523-1755.1999.00527.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Barayev O, Hawley CE, Wellman H, Gerlovin H, Hsu W, Paik JM, Mandel EI, Liu CK, Djousse L, Gaziano JM, Gagnon DR and Orkaby AR: Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease. JAMA Netw Open, 2023; 6: e2346373","DOI":"10.1001\/jamanetworkopen.2023.46373"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Herrera-Gomez F, Chimeno MM, Martin-Garcia D, Lizaraso-Soto F, Maurtua-Briseno-Meiggs A, Grande-Villoria J, Bustamante-Munguira J, Alamartine E, Vilardell M, Ochoa-Sangrador C and Alvarez FJ: Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses. Sci Rep, 2019; 9: 8951","DOI":"10.1038\/s41598-019-45431-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Vendeville N, Lepage MA, Festa MC and Mavrakanas TA: Clinical Outcomes of Renin-Angiotensin-Aldosterone Blockade in Patients With Advanced Chronic Kidney Disease: A Systematic Review and Meta-analysis. Can J Cardiol, 2024; 40: 1718-1728","DOI":"10.1016\/j.cjca.2024.02.027"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Mazzarino M, Cetin E, Bartosova M, Marinovic I, Ipseiz N, Hughes TR, Schmitt CP, Ramji DP, Labeta MO and Raby AC: Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology. Front Immunol, 2023; 14: 1240679","DOI":"10.3389\/fimmu.2023.1240679"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Musial K and Zwolinska D: Heat shock proteins in chronic kidney disease. Pediatr Nephrol, 2011; 26: 1031-1037","DOI":"10.1007\/s00467-010-1709-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB and Arditi M: Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A, 2004; 101: 10679-10684","DOI":"10.1073\/pnas.0403249101"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Fujiwara M, Matoba T, Koga JI, Okahara A, Funamoto D, Nakano K, Tsutsui H and Egashira K: Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischaemia-reperfusion injury by inhibiting monocyte-mediated inflammation in mice. Cardiovasc Res, 2019; 115: 1244-1255","DOI":"10.1093\/cvr\/cvz066"},{"key":"28","unstructured":"28) Kellerman PS: Cellular and metabolic consequences of chronic ischemia on kidney function. Semin Nephrol, 1996; 16: 33-42"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Zhu YT, Wan C, Lin JH, Hammes HP and Zhang C: Mitochondrial Oxidative Stress and Cell Death in Podocytopathies. Biomolecules, 2022; 12:","DOI":"10.3390\/biom12030403"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Fotheringham AK, Gallo LA, Borg DJ and Forbes JM: Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney? Nutrients, 2022; 14:","DOI":"10.3390\/nu14132675"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Pereira M, Durso DF, Bryant CE, Kurt-Jones EA, Silverman N, Golenbock DT and Gazzinelli RT: The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways. Cell Rep, 2022; 40: 111225","DOI":"10.1016\/j.celrep.2022.111225"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Xia X, Cui J, Wang HY, Zhu L, Matsueda S, Wang Q, Yang X, Hong J, Songyang Z, Chen ZJ and Wang RF: NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity, 2011; 34: 843-853","DOI":"10.1016\/j.immuni.2011.02.022"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K and Cohen J: A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med, 2010; 38: 1685-1694","DOI":"10.1097\/CCM.0b013e3181e7c5c9"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/5\/33_66076\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:24:55Z","timestamp":1777692295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/5\/33_66076\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.66076","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"66076"}}